Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein

Abstract Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (TKI), has been investigated in a variety of malignant tumors. This retrospective study was designed to investigate the efficacy and safety of anlotinib as first- or second-line therapy for advanced or metastatic hepatocellular ca...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jianping Chang, Bowen Xu, Zhiyu Li, Zhicheng Wei, Xu Che, Jianqiang Cai, Yanjiang Yin, Xinyu Bi
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2025-08-01
Sarja:	Scientific Reports
Aiheet:	Advanced hepatocellular carcinoma Anlotinib Tyrosine kinase inhibitor Α-fetoprotein Prognostic factor Predictive factor
Linkit:	https://doi.org/10.1038/s41598-025-14759-6
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!